68Ga-NOTA-3P-TATE-RGD与68Ga-DOTATATE在胃肠胰神经内分泌肿瘤患者中的前瞻性头对头比较
这项前瞻性研究纳入35例病理证实的胃肠胰神经内分泌肿瘤患者,在同一组患者中头对头比较68Ga-NOTA-3P-TATE-RGD与68Ga-DOTATATE PET/CT。两种显像剂均能检出全部患者的阳性病灶,68Ga-NOTA-3P-TATE-RGD在肝转移灶检出数更多且肝病灶靶本比更高,在FDG阳性肿瘤中摄取倾向更高。
要点
- 35例胃肠胰神经内分泌肿瘤患者中,68Ga-NOTA-3P-TATE-RGD与68Ga-DOTATATE均检出至少一个阳性病灶。
- 68Ga-NOTA-3P-TATE-RGD检出肝病灶634个,多于68Ga-DOTATATE的532个(P=0.021)。
- 肝病灶靶本比68Ga-NOTA-3P-TATE-RGD为8.4±5.5,高于68Ga-DOTATATE的4.7±3.7(P<0.001)。
核心结论
- 68Ga-NOTA-3P-TATE-RGD在肝转移灶检出方面优于68Ga-DOTATATE,且肝病灶靶本比更高。
- 68Ga-NOTA-3P-TATE-RGD在FDG阳性神经内分泌肿瘤中倾向于较68Ga-DOTATATE显示更高摄取。
研究设计与样本
- 前瞻性研究,纳入35例组织学证实的胃肠胰神经内分泌肿瘤患者(5例1级、28例2级、2例3级肿瘤)。
- 原发肿瘤主要来源于胰腺和直肠。
- 所有患者在一周内分别接受68Ga-NOTA-3P-TATE-RGD PET/CT与68Ga-DOTATATE PET/CT扫描并进行头对头比较。
- 16例患者另接受常规18F-FDG PET/CT。
- 图像采用肿瘤最大标准化摄取值(SUVmax)和靶本比进行半定量评价。
主要发现
- 所有患者在两种扫描中均至少有一个阳性病灶。
- 68Ga-NOTA-3P-TATE-RGD图像与68Ga-DOTATATE图像分别检出1190个和1106个病灶(P=0.152)。
- 68Ga-NOTA-3P-TATE-RGD检出肝病灶634个,多于68Ga-DOTATATE的532个(P=0.021)。
- 两种显像剂检出原发肿瘤(20 vs. 20,P=1.000)、淋巴结转移(101 vs. 102,P=0.655)和骨转移(381 vs. 398,P=0.244)的结果相当。
- 12例患者肿瘤SUVmax在68Ga-NOTA-3P-TATE-RGD显著高于68Ga-DOTATATE(27.2±13.6 vs. 19.5±10.0,P<0.001),其中9例有18F-FDG PET/CT且均为FDG阳性;其余23例患者68Ga-DOTATATE摄取显著高于68Ga-NOTA-3P-TATE-RGD(22.3±16.4 vs. 11.9±7.5,P<0.001),其中7例有18F-FDG PET/CT且6例为FDG阴性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to compare 68 Ga-NOTA-3P-TATE-RGD, a dual somatostatin receptor 2- and integrin αVβ3-targeting tracer, to 68 Ga-DOTATATE in a single group of patients with gastroenteropancreatic (GEP)-neuroendocrine tumours (NETs). METHODS: Thirty-five patients with histologically confirmed GEP-NETs (5 grade 1, 28 grade 2, and 2 grade 3 tumours) were prospectively enrolled with informed consent. The primary tumour mainly originated from the pancreas and rectum. All patients were scanned with both 68 Ga-NOTA-3P-TATE-RGD PET/CT and 68 Ga-DOTATATE PET/CT within a week and compared on a head-to-head basis. Sixteen patients also had conventional 18F-FDG PET/CT. Images were evaluated semi-quantitatively using maximum standardized uptake values (SUVmax) of tumour and tumour-to-background ratio. RESULTS: All patients had at least one positive lesion on each of the two scans. A total of 1190 and 1106 lesions were detected on 68 Ga-NOTA-3P-TATE-RGD images and 68 Ga-DOTATATE images, respectively (P = 0.152). 68 Ga-NOTA-3P-TATE-RGD PET/CT revealed significantly more lesions in the liver than 68 Ga-DOTATATE PET/CT (634 vs. 532, P = 0.021). Both tracers produced comparable results for detecting primary tumours (20 vs. 20, P = 1.000), lymph node metastases (101 vs. 102, P = 0.655), and bone metastases (381 vs. 398, P = 0.244). The tumour SUVmax in 12 patients was significantly higher for 68 Ga-NOTA-3P-TATE-RGD than for 68 Ga-DOTATATE (27.2 ± 13.6 vs. 19.5 ± 10.0, P < 0.001); among them, 9 had 18F-FDG PET/CT and all were found to be FDG-positive. The remaining 23 patients had significantly higher 68 Ga-DOTATATE uptake than 68 Ga-NOTA-3P-TATE-RGD uptake (22.3 ± 16.4 vs. 11.9 ± 7.5, P < 0.001); among them, 7 had 18F-FDG PET/CT and 6 were FDG-negative. Generally, 68 Ga-DOTATATE demonstrated higher tumour SUVmax than 68 Ga-NOTA-3P-TATE-RGD (20.8 ± 16.0 vs. 14.2 ± 8.9, P < 0.001), including primary tumours, liver lesions, lymph node lesions, and bone lesions. However, the tumour-to-background ratio of liver lesions was significantly higher when using 68 Ga-NOTA-3P-TATE-RGD compared with that when using 68 Ga-DOTATATE (8.4 ± 5.5 vs. 4.7 ± 3.7, P < 0.001). CONCLUSION: 68 Ga-NOTA-3P-TATE-RGD performed better than 68 Ga-DOTATATE in detection of liver metastases with a higher tumour-to-background ratio. Moreover, 68 Ga-NOTA-3P-TATE-RGD tended to demonstrate higher uptake over 68 Ga-DOTATATE in FDG-avid NETs. TRIAL REGISTRATION: Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging (NCT02817945, registered 5 November 2018). URL OF REGISTRY: https://clinicaltrials.gov/ct2/show/NCT02817945.
引用
- Jiang Y, Liu Q, Wang G, et al. A prospective head-to-head comparison of 68 Ga-NOTA-3P-TATE-RGD and 68 Ga-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2022. PMID: 35657429. doi:10.1007/s00259-022-05852-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。